Clinical Trials

COVID-19 Update

At Dendreon Pharmaceuticals LLC, the health and well-being of our employees, patients, and communities are of high importance.

Our priority remains serving the needs of our patients, healthcare professionals, and our community. During these unprecedented times, Dendreon manufacturing facilities remain open and operational. As an added precautionary measure, Dendreon has limited manufacturing facility access to essential personnel only. This preserves our ability to continue serving healthcare professionals and patients, while protecting the health of our employees.

We are currently unaware of any logistical issues related to the manufacture of PROVENGE^® (sipuleucel-T). For up‐to‐date information, please contact Dendreon On Call at (877) 336-3736 and select option #2.

Many of the apheresis collection centers, which are operated independently of Dendreon, are taking additional measures to maintain patient safety in response to COVID‐19, including travel‐related recommendations and pre‐screening calls to assess patients’ health. The reasons for these efforts are to minimize the number of patients unable to undergo leukapheresis and to keep every apheresis center as safe as possible for patients and staff. Please reach out to your apheresis collection center for additional information.

Dendreon will continue to monitor and assess the COVID-19 situation in the United States and will update this notice as necessary. For further information, please send your requests to MAC@dendreon.com